Polymyalgia rheumatica does go away for most people, but “going away” typically means years of treatment rather than weeks or months. The median duration of steroid therapy sits around two and a half to three years, and a significant minority of patients need treatment considerably longer than that. The disease follows an unpredictable course with frequent relapses, and even after the core inflammation settles, lingering symptoms like fatigue and poor sleep can persist well beyond what many patients expect.
How Long Treatment Usually Lasts
The standard treatment for polymyalgia rheumatica (PMR) is low-dose prednisone, and most patients respond dramatically within the first few days. That fast relief can create the impression that the disease will be short-lived. In practice, the treatment timeline stretches much further. One study tracking PMR patients found a mean steroid duration of about 30 months, with a range spanning roughly one to nine years.1Annals of the Rheumatic Diseases. Duration of Steroid Treatment in Polymyalgia Rheumatica Another long-term follow-up reported a median therapy duration of just over 37 months and estimated that about 40 percent of patients would require treatment for more than four years.2PubMed. Polymyalgia rheumatica. Duration of therapy and long-term outcome
Almost everyone with PMR needs at least a year on corticosteroids. One study found that 97 percent of patients were still on treatment at the one-year mark, and roughly a third still required moderate doses at that point.3Annals of the Rheumatic Diseases. Prognosis and management of polymyalgia rheumatica The typical approach is a slow, gradual taper: the starting dose brings symptoms under control, and then the dose is reduced in small increments over many months. Rushing the taper is one of the most common triggers for a flare.
Two Groups of Patients
Researchers have observed that PMR patients roughly split into two populations. One group has a more limited form of the disease. For these patients, steroids can be permanently stopped after about two years, and the disease does not return. The other group has a more stubborn course and needs ongoing low-dose steroids for years. In the long-term follow-up cited above, patients who were able to stop treatment did so after an average of about 24 months, while those in the longer-treatment group pushed the overall median well past three years.2PubMed. Polymyalgia rheumatica. Duration of therapy and long-term outcome
A cohort study of people with PMR found that about 40 percent were still taking glucocorticoids at follow-up, at a median daily dose of 5 mg. Those still on treatment tended to be older, were more likely to live alone, and were more likely to have self-adjusted their own steroid doses rather than following a structured taper with their doctor.4Rheumatology Advances in Practice. Long-term use of glucocorticoids for polymyalgia rheumatica: follow-up of the PMR Cohort Study Self-managing steroid doses can lead to either undertreating (triggering flares) or overtreating (prolonging unnecessary exposure to side effects), both of which make the overall illness drag on.
What Makes Relapses So Common
Relapses are one of the main reasons PMR feels like it does not go away. Rates vary across studies, but roughly half of patients experience at least one relapse during their treatment course. One early study reported flares in 56 percent of patients.2PubMed. Polymyalgia rheumatica. Duration of therapy and long-term outcome Even after steroids are fully withdrawn, about 10 percent of patients relapse and need to restart treatment.1Annals of the Rheumatic Diseases. Duration of Steroid Treatment in Polymyalgia Rheumatica
Several factors affect relapse risk. Higher inflammatory markers at diagnosis, particularly a high erythrocyte sedimentation rate (ESR), have been linked to both a longer treatment course and a greater chance of relapse.5Annals of the Rheumatic Diseases (BMJ Journals). Current evidence for therapeutic interventions and prognostic factors in polymyalgia rheumatica Female sex and having peripheral joint involvement at the outset are also potential risk factors for a worse prognosis, though the evidence on each of these is somewhat inconsistent across studies.
Age at diagnosis plays a role as well. Patients diagnosed before age 60 had a lower relapse rate (about 35 percent) compared with those diagnosed later (about 55 percent).6Autoimmunity Reviews. Impact of age at diagnosis in polymyalgia rheumatica: A retrospective cohort study of 218 patients Older patients also took longer to reach remission, averaging about five months compared with four months for younger patients.7PubMed. Time to remission and steroid doses in older and younger patients with polymyalgia rheumatica Given that PMR overwhelmingly strikes people over 50, a substantial number of patients fall into the higher-relapse-risk group simply by virtue of their age.
The Giant Cell Arteritis Connection
One of the more serious complications that can extend and worsen PMR’s course is giant cell arteritis (GCA), an inflammation of the large blood vessels. PMR and GCA are closely related conditions that frequently overlap.8The Lancet. Polymyalgia rheumatica and giant-cell arteritis Some patients with PMR have subclinical GCA, meaning they have vessel inflammation detectable on imaging even though they have no obvious GCA symptoms like headache or vision changes.
This hidden vascular inflammation substantially changes the prognosis. In one study, patients with subclinical GCA had a relapse rate of 62 percent, compared with just 16 percent in those with isolated PMR.9PubMed. Subclinical giant cell arteritis increases the risk of relapse in polymyalgia rheumatica Those who relapsed had also been tapered faster in the first three months. The implication is that some patients who seem to have stubborn, relapsing PMR actually have an underlying vascular component that needs different management. If you keep flaring despite what seems like appropriate treatment, your doctor may consider imaging to look for subclinical GCA.
Why the Inflammation Keeps Coming Back
PMR is driven by an immune system that is attacking the body’s own tissues, particularly the bursae (fluid-filled sacs near joints) and the lining of the shoulder and hip joints. The key player is a signaling molecule called IL-6, which drives inflammation and also contributes to many of the systemic symptoms PMR patients know well, including fatigue, sleep problems, and mood changes.10PubMed. Understanding the immunopathophysiology of polymyalgia rheumatica: implications for treatment
Recent research has clarified that macrophages (a type of immune cell) dominate the inflamed tissue in PMR and are driven to overproduce IL-6 by another molecule called GM-CSF. Without GM-CSF, IL-6 production was limited in laboratory experiments.11PubMed. GM-CSF drives IL-6 production by macrophages in polymyalgia rheumatica This matters because prednisone suppresses inflammation broadly but does not necessarily fix whatever is causing the immune system to misbehave in the first place. So when you taper the steroid, the underlying process can flare right back up. In some refractory cases, additional inflammatory pathways and markers seem to be involved, which may explain why certain patients resist standard glucocorticoid treatment.12PubMed. Immune system activation in polymyalgia rheumatica: Which balance between autoinflammation and autoimmunity? A systematic review
Steroid Side Effects Over Time
Because PMR requires long treatment, the side effects of prednisone become a central concern. Even at the low doses used for PMR, prolonged steroid therapy carries real risks. A retrospective study of over 200 PMR patients found that 43 percent experienced at least one adverse event, with osteoporosis and fragility fractures being the most common. The risk of these complications increased significantly after two years of treatment, and higher cumulative steroid doses were tied to more fractures and high blood pressure.13The Journal of Rheumatology. Adverse Events During Longterm Low-dose Glucocorticoid Treatment of Polymyalgia Rheumatica: A Retrospective Study
Another study found that the risks of diabetes, vertebral fractures, and hip fractures were two to five times higher in PMR patients compared with age-matched people without the condition. Older age at diagnosis, female sex, and higher cumulative prednisone doses all independently increased the risk of adverse events.14PubMed. Adverse outcomes of antiinflammatory therapy among patients with polymyalgia rheumatica These findings are a strong argument for tapering steroids as quickly as the disease allows, and for considering steroid-sparing medications when the standard approach is not working.
Steroid-Sparing Options
For patients who cannot taper off prednisone without relapsing, or who are accumulating unacceptable side effects, there are alternatives. Methotrexate is the most commonly used steroid-sparing agent, and current guidelines include it as an option for relapsing or refractory PMR. A newer option that has shown promise is tocilizumab, a drug that directly blocks IL-6, the key inflammatory molecule in PMR. A multicenter retrospective study comparing tocilizumab with both prednisone alone and methotrexate found that patients on tocilizumab achieved dramatically lower prednisone doses. About 80 percent of the tocilizumab group were able to stop prednisone entirely, compared with roughly 28 percent on methotrexate and 19 percent on prednisone alone.15Annals of the Rheumatic Diseases. Tocilizumab Is Significantly Steroid-Sparing Compared with Methotrexate in Polymyalgia Rheumatica: A Multicenter Retrospective Study (NTMC-KEIO PMR Study)
These drugs do not cure PMR. They help manage the inflammation with less reliance on steroids, which means fewer steroid-related complications. They are generally reserved for people who have already tried standard prednisone therapy and either cannot tolerate it or keep flaring during the taper.
Fatigue and Sleep Problems That Outlast the Pain
One of the most frustrating aspects of PMR for patients is that even when blood tests normalize and the joint pain improves, other symptoms can linger. A study that followed PMR patients for nearly two years after starting treatment found that about 35 percent still suffered severe fatigue at follow-up, compared with just 3 percent of controls. Poor sleep quality was even more common: 84 percent of PMR patients reported it at follow-up, compared with 56 percent of matched controls.16The Journal of Rheumatology. More Than Pain and Stiffness: Persistent Fatigue and Sleep Disturbance in Polymyalgia Rheumatica These symptoms persisted even when standard measures of disease activity were low.
This disconnect between lab markers and how you actually feel is something many PMR patients encounter. Your doctor may say your inflammation is under control based on blood tests, while you are still dealing with crushing tiredness and broken sleep. The IL-6-driven disruption of sleep and energy pathways, described earlier, is one likely explanation. For some patients, these symptoms are the hardest part of the disease, and they can persist well beyond the point where the classical shoulder and hip stiffness has resolved.
When Stopping Steroids Feels Worse Than the Disease
A particularly tricky issue arises when patients try to stop prednisone after remission. Long-term steroid use suppresses the body’s own cortisol production, and when the external steroids are withdrawn, the adrenal glands may not pick up the slack immediately. The resulting adrenal insufficiency can cause fatigue, muscle pain, and general malaise that feel remarkably similar to a PMR flare.17Rheumatology. Adrenal insufficiency in prednisolone-treated patients with polymyalgia rheumatica or giant cell arteritis—prevalence and clinical approach
This mimicry creates a vicious cycle. Patients feel awful after lowering their dose, assume the PMR is back, and go back up on steroids. Each time this happens, the adrenal glands stay suppressed for even longer. Breaking this cycle often requires very slow tapering at the lowest doses, sometimes dropping by just half a milligram at a time over weeks, and occasionally formal testing of adrenal function. If your symptoms return only at doses below 5 mg of prednisone and are dominated by fatigue rather than the classic bilateral shoulder stiffness, adrenal insufficiency is worth considering as a cause.
Monitoring for Relapse
Blood tests remain the main tool for tracking PMR activity and deciding when it is safe to taper. ESR and C-reactive protein (CRP) are the two markers most commonly used, but they behave differently. A prospective study found that ESR at diagnosis was the better predictor of future relapse. People with an ESR above 40 at diagnosis had roughly five times the relapse risk, while elevated CRP roughly doubled it.18Seminars in Arthritis and Rheumatism. Erythrocyte sedimentation rate and C-reactive protein in the evaluation of disease activity and severity in polymyalgia rheumatica: A prospective follow-up study However, CRP was a more sensitive indicator of current, active disease. In over 60 percent of relapse episodes where ESR was normal, CRP was elevated. If your ESR comes back normal but you are still symptomatic, asking your doctor to check CRP can help clarify whether the disease is truly quiet.
PMR Does Not Shorten Your Life
For all the frustrations of a long treatment course and frequent relapses, the reassuring news is that isolated PMR does not appear to increase mortality. A 38-year population-based study found that survival in people with PMR without concurrent GCA was essentially the same as in the general population.19PubMed Central. Mortality in polymyalgia rheumatica: a 38-year prospective population-based cohort study from Southern Norway A separate large retrospective cohort study confirmed this, finding no increase in the overall risk of death among PMR patients compared with matched controls.20PubMed. Mortality Among Patients With Polymyalgia Rheumatica: A Retrospective Cohort Study Causes of death were broadly similar between the two groups, though there was a very slight increase in vascular deaths among PMR patients. The condition is disabling and affects quality of life, but it is not a disease that shortens life expectancy when GCA is not present.
What PMR Can Be Confused With
Part of why some people feel their PMR never fully resolves is that the initial diagnosis may not have been entirely right. PMR is a clinical diagnosis, meaning there is no single blood test or imaging finding that confirms it. The hallmarks are bilateral shoulder and hip stiffness in someone over 50 with elevated inflammatory markers. But those same symptoms can appear in rheumatoid arthritis, late-onset inflammatory arthritis, certain cancers, thyroid disorders, and infections. The clinical overlap between PMR and seronegative rheumatoid arthritis is striking, with some researchers suggesting they may be different presentations of a similar underlying process.21JAMA Network (Archives of Internal Medicine). Diagnostic Dilemmas in Polymyalgia Rheumatica If you were diagnosed with PMR but your symptoms have behaved unusually, spreading to smaller joints, failing to respond to moderate prednisone doses, or lasting far longer than expected, it may be worth asking your rheumatologist to revisit the diagnosis.
Exercise and Physiotherapy
Steroids control the inflammation, but they do not rebuild the strength and mobility that PMR takes away. Shoulder stiffness in particular can become persistent, and deconditioning from months of limited activity compounds the problem. A survey of UK physiotherapists managing PMR patients found that 89 percent prescribed individualized graded exercises focusing on the upper limbs, aimed at improving movement, strength, and the ability to do daily tasks.22PubMed Central. Physiotherapy for the Management of Polymyalgia Rheumatica: Results From a UK Cross‐Sectional Survey Gentle exercise during treatment is generally safe and encouraged. It will not cure PMR, but it can shorten the functional recovery once the disease does eventually burn out. Many patients find that without active rehabilitation, shoulder range of motion does not fully return on its own even after all inflammation is gone.